Aurobindo Pharma gets FDA approval for generic equivalent of Xarelto
The anticoagulant drug, which has an estimated US market size of $447 million, is set to be launched in the first quarter of the 2025-26 fiscal.
13 April, 2025•2 min
0
13 April, 2025•2 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
SUBSCRIBE
Already have an account? Sign In
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
Business
SEBI rejects Anil Ambani's settlement plea in Yes Bank case
The market regulator plans to order Rs 1,828 crore in investor compensation after rejecting a settlement offer in the Yes Bank AT-1 bond case.
You may also like
Business
Has Aurobindo Pharma left its wild swings behind?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
Business
Is Aurobindo Pharma the most underrated pharma company?
The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.